184357-44-6

Basic information

• Product Name: Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI);Tert-butyl 3-Hydroxy-2,2-dimethylpropylcarbamate;3-(Boc-aMino)-2,2-diMethyl-1-propanol;3-(Boc-amino)-2,2-dimethylpropanol;tert-Butyl (3-hydroxy-2,2-dimethylpropyl)
• CAS NO: 184357-44-6
• Molecular Formula: C₁₀H₂₁NO₃
• Molecular Weight: 203.27864
• Product Categories: N-BOC
• Mol File: 184357-44-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 311 °C at 760 mmHg
• Flash Point: 141.9 °C
• Appearance: /
• Density: 0.998 g/cm³
• Vapor Pressure: 5.16E-05mmHg at 25°C
• Refractive Index: 1.454
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI)(184357-44-6)
• EPA Substance Registry System: Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI)(184357-44-6)

Safety Data

• Hazardous Substances Data: 184357-44-6(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C9H19NO3. It is an ester of carbamic acid and is also known as tert-butyl (3-hydroxy-2,2-dimethylpropyl)carbamate. Carbamic acid, (3-hydroxy-2,2-dimethylpropyl)-, 1,1-dimethylethyl ester (9CI) is commonly used as a pharmaceutical intermediate in the synthesis of various drugs, particularly in the pharmaceutical industry. It is also used as a reagent in organic synthesis and as a stabilizer in the production of polymers. This chemical exhibits moderate toxicity and should be handled with caution.

InChI:InChI=1/C10H21NO3/c1-9(2,3)14-8(13)11-6-10(4,5)7-12/h12H,6-7H2,1-5H3,(H,11,13)

Upstream product

• 26734-09-8 3-amino-2,2-dimethylpropan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 529409-31-2 N-(p-toluenesulfonyl)-N-(tert-butoxycarbonyl)-methallylamine 
• 91230-06-7 3--2-methylprop-1-ene 
• 18303-04-3 N-[(tert-butoxy)carbonyl]-4-methylbenzenesulfonamide 

Downstream Products

• 889108-00-3 2-(3-tert-butoxycarbonylamino-2,2-dimethylpropoxy)-4-(tert-butyl)-benzoic acid 
• 889120-62-1 2-[2-(3-tert-butoxycarbonylamino-2,2-dimethylpropoxy)-4-(tert-butyl)benzoyl-amino]-N-(5-chloropyridin-2-yl)benzamide 
• 889120-63-2 2-[2-(3-amino-2,2-dimethylpropoxy)-4-(tert-butyl)benzoylamino]-N-(5-chloropyridin-2-yl)benzamide 
• 1443216-72-5 C₂₉H₃₉N₅O₆ 
• 16047-86-2 2,2-dimethyl-3-(methylamino)propan-1-ol 
• 180181-02-6 3-(tert-Butoxycarbonyl)amino-2,2-dimethylpropanoic Acid 
• 856244-25-2 (2S)-3-{4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-2-{2-[3-(tert-butoxycarbonylamino)-3-methylpropoxycarbonylamino]ethylsulfonylamino}propionic acid 
• 889125-79-5 methyl 2-(3-tert-butoxycarbonylamino-2,2-dimethylpropoxy)-4-(tert-butyl)-benzoate 

Relevant articles and documents

Lead evaluation of tetrahydroquinolines as nonsteroidal selective androgen receptor modulators for the treatment of osteoporosis

Tetrahydroquinoline (THQ) was deemed to be a suitable scaffold for our nonsteroidal selective androgen receptor modulator (SARM) concept. We adapted the strategy of switching the antagonist function of cyano-group-containing THQ (CN-THQ) to the agonist function and optimized CN-THQ as an orally available drug candidate with suitable pharmacological and ADME profiles. Based on binding mode analyses and synthetic accessibility, we designed and synthesized a compound that possesses a para-substituted aromatic ring attached through an amide linker. The long-tail THQ derivative 6-acetamido-N-(2-(8-cyano-3a,4,5,9b- tetrahydro-3H-cyclopenta[c]quinolin-4-yl)-2-methylpropyl)nicotinamide (1 d), which bears a para-acetamide-substituted aromatic group, showed an appropriate in vitro biological profile, as expected. We considered that the large conformational change at Trp741 of the androgen receptor (AR) and the hydrogen bond between 1 d and helix 12 of the AR could maintain the structure of the AR in its agonist form; indeed, 1 d displays strong AR agonistic activity. Furthermore, 1 d showed an appropriate in vivo profile for use as an orally available SARM, displaying clear tissue selectivity, with a separation between its desirable osteoanabolic effect on femoral bone mineral density and its undesirable virilizing effects on the uterus and clitoral gland in a female osteoporosis model. Long-tail THQ as a SARM: We describe the lead evaluation process of tetrahydroquinolines (THQs) as nonsteroidal selective androgen receptor modulators (SARMs). The strategy of switching from AR antagonist to AR agonist was successfully applied to CN-THQ, and we identified a long-tail THQ as a novel SARM. This new THQ showed a certain degree of tissue selectivity, with a separation between its desirable osteoanabolic effect and its undesirable virilizing effects in a female osteoporosis model. Copyright

3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS

The present invention relates to bisaryl lactam compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the compounds of this invention include a compound of Formula (I):

LSD1 INHIBITORS AND USES THEREOF

Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSDl.